Vero Biotech Secures $50M in Funding

Vero Biotech LLC, an Atlanta, Georgia-based biotechnology company, closed a senior secured term loan of $50m.

Runway Growth Capital provided the financing.

Led by Brent V. Furse, CEO and President, Vero Biotech (formerly known as GeNO LLC) is a biotechnology company focused on the design, development, and commercialization of next-generation products to meet the needs of patients with a variety of pulmonary and cardiac diseases. The

company developed the GENOSYL® Delivery System (GENOSYL DS), a inhaled nitric oxide delivery system approved by the U.S. Food and Drug Administration (FDA).  The GENOSYL DS transforms the delivery and use of nitric oxide, a vasodilator proven to play a critical role in the care of patients with adult respiratory distress syndrome and persistent pulmonary hypertension of the neonate. The GENOSYL® Delivery System was authorized by the U.S. FDA for expanded emergency use access for patients with cardiopulmonary complications associated with COVID-19; was granted an emergency IND for at-home use; and approved for interhospital transport use in ground, fixed-wing and rotary-wing transport environments.

Read original article here.